Latest AI and machine learning research in alzheimer's disease for healthcare professionals.
The indicator cell assay platform (iCAP) is a novel next-generation approach for blood-based diagnostics that uses standardized cells as biosensors to amplify weak disease signals in blood. We developed an Alzheimer’s disease iCAP (AD-iCAP) for early detection at the mild cognitive impairment/mild dementia stages. To develop the assay, patient plasma is incubated with standardized neurons, which t...
Sleep disturbances and altered circadian rhythms are well-documented in both physiological and biological studies of dementia. The exact causal relationship remains unclear. Several other long-term health conditions may also influence sleep patterns. Examining sleep patterns in relation to chronological ageing and the variations and progression of dementia, considering factors such as age, sex, an...
Synthetic clinical data are increasingly important for advancing AI in healthcare, given strict privacy constraints on real-world EHRs, limited availa...
Explainable Artificial Intelligence (XAI) methods enhance the diagnostic efficiency of clinical decision support systems by making the predictions of ...
Disrupted brain iron metabolism and activated ferroptosis during ageing constitute significant precursors to neurodegenerative diseases. However, whet...
Accurate disease prognosis is essential for patient care but is often hindered by the lack of long-term data. This study explores deep learning traini...
Sleep electroencephalographic (EEG) microstructures are closely related to cognition and undergo age-dependent changes. However, their multidimensiona...
Diabetes, hypertension, and dyslipidemia are major risk factors for cardiovascular (CVD), cerebral, and renal diseases (RD). However, the underlying m...
Covert cerebrovascular disease (CCD), comprising covert brain infarction (CBI) and white matter disease (WMD), is common in older adults and linked to...
Prior research suggests that meditation may slow brain aging and reduce the risk of Alzheimer’s disease (AD). However, we lack research systematically...
Neuron loss is a key feature of neurodegenerative diseases often leading to brain atrophy detectable through magnetic resonance imaging (MRI). Various...
Alzheimer’s Disease and Related Dementias (ADRD) affect millions worldwide and can begin over a decade before symptoms appear. ADRD are generally irre...
Cognitive decline affects approximately 40% of Parkinson’s disease (PD) patients within 10 years of diagnosis, progressing to dementia in 80% of patie...
Alzheimer’s disease (AD) involves early molecular changes beyond amyloid-β (Aβ) and tau, that create heterogeneous disease biology, giving rise to var...
Retinal fundus images offer a non-invasive window into systemic aging. Here, we fine-tuned a foundation model (RETFound) to predict chronological age ...
Early and accurate prediction of Alzheimer’s disease (AD) from accessible clinical data remains a significant challenge in healthcare. This study prop...
APOE-ε4, the strongest genetic risk factor for Alzheimer’s disease (AD), is linked to early motor vulnerability, including subtle speech control chang...
Alzheimer’s Disease (AD) is a progressive neurodegenerative disorder that primarily affects cognitive function. Early detection is a crucial factor in...
Predicting the likelihood of developing Alzheimer’s disease (AD) dementia in at-risk individuals is important for the design of and optimal recruitmen...
Clinicians currently lack reliable tools to determine, at the point of mild cognitive impairment (MCI), which individuals will progress to Alzheimer’s...